ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1616

Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley

Sukesh Sukumaran1, Reshma Patel2 and Deepika Singh3, 1Valley Children's Healthcare, Madera, CA, 2Valley Children's Hospital, Madera, CA, 3Valley Children Healthcare, Madera, CA

Meeting: ACR Convergence 2021

Keywords: COVID-19, Pediatric rheumatology, prevention, race/ethnicity, Vaccination

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of the acceptability of a COVID-19 vaccine among children with autoimmune diseases may help rheumatologists to develop resources and best practices for shared decision making when offering the COVID-19 vaccine to their patients.

The objective of this study is to evaluate the knowledge and perceptions regarding COVID-19 vaccination and determine the self-reported likelihood of receiving a hypothetical COVID-19 vaccine among children with rheumatic diseases.

Methods: We surveyed a convenience sample of 54 children seen in our pediatric rheumatology clinic in May 2021 to estimate the respondents’ perceptions regarding the COVID-19 vaccine. Respondents were asked questions to assess their knowledge about COVID-19 and willingness to accept the COVID-19 vaccine.

Results: Of the 54 patients surveyed, the median age of the participants was 12.9 (range 5-18) years and 78% were females. Racial/ethnic minorities contributed about 52% among the respondents. Forty percent of the respondents had juvenile idiopathic arthritis.

Regarding knowledge about COVID-19 disease, 83% agreed with the statement that COVID-19 was caused by a virus but 20% “agreed” or “strongly agreed” with the statement that influenza and COVID-19 were caused by the same virus. Twenty-one percent of respondents perceived that COVID-19 patients were symptomatic, sick, and required hospitalization. Our respondents gathered information about the pandemic from social media (45%) and television (50%). Sixty-eight percent of patients discussed COVID-19 and its implications with their doctor.

Regarding perceptions about the vaccine, 82% of respondents “strongly agreed” or “agreed” with the statement, “There is misinformation regarding COVID-19 vaccine on the internet”. Greater than 75% of our respondents practiced social distancing, hand hygiene and wore masks in public spaces. Although 55% of our respondent reported willingness to accept a COVID-19 vaccine, only 39% perceived that the vaccine would provide protection from the disease and 85% stated concerns about side effects. Respondents cited greater concerns about vaccine side effects when compared to disease complications (40%).

We found that the acceptability of the COVID-19 vaccine was higher among whites when compared to racial/ethnic minorities (84% vs. 58%). Similarly, concerns about side effects and was higher among racial/ethnic minorities. Willingness to pay for the vaccine was also lower among racial/ethnic minorities.

Conclusion: Our study identifies the specific knowledge gaps and incorrect perceptions about COVID-19 and the COVID-19 vaccine among children with rheumatic diseases. Concerns about the effectiveness of the vaccine and potential side effects were high. We found that self-reported likelihood of vaccine acceptability was lower among racial/ethnic minorities when compared to whites. The results of this survey study may help inform public health campaigns to address COVID-19 vaccine hesitancy among these special populations.


Disclosures: S. Sukumaran, None; R. Patel, None; D. Singh, None.

To cite this abstract in AMA style:

Sukumaran S, Patel R, Singh D. Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/acceptability-of-covid-19-vaccine-among-pediatric-rheumatology-patients-in-californias-central-valley/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acceptability-of-covid-19-vaccine-among-pediatric-rheumatology-patients-in-californias-central-valley/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology